ArticleBMC nephrology2026
Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrimary membranous nephropathy (pMN) is characterized by a prolonged course, frequent relapses, and variable treatment responses. While obinutuzumab (OBI) demonstrates promising efficacy in B-cell depletion, its direct comparison with the combination regimen of rituximab (RTX) plus tacrolimus (TAC) remains limited. This study aimed to evaluate the efficacy and safety of OBI monotherapy versus RTX + TAC in patients with refractory pMN.
methodsWe retrospectively enrolled 28 patients with biopsy-proven pMN from a single center, assigned to RTX + TAC (n = 13) or OBI (n = 15) groups according to treatment regimen. Clinical remission, immunological remission (IR), and adverse events were assessed over 24 months of follow-up.
resultsNo significant differences were observed in serum creatinine, estimated glomerular filtration rate (eGFR), serum albumin, urine protein excretion, or anti-phospholipase A2 receptor (PLA2R) antibody titers between the two study groups. In contrast, disease duration differed substantially between groups: the OBI group exhibited a significantly longer median disease duration (87.7 (29, 168) months) compared with the RTX + TAC group (14 (7, 36) months). At the end of follow-up, the cumulative clinical remission rate (achieving complete remission or partial remission) was 89.1% among 11 patients included in the RTX + TAC group, and 92.9% among 14 patients in the OBI group. For IR, the cumulative IR rate was 60.0% among 10 patients in the RTX + TAC group and 90.9% among 11 patients in the OBI group. Kaplan-Meier survival analysis further demonstrated a statistically significant difference in cumulative IR rates between the two groups (P = 0.03).
conclusionOBI monotherapy achieved comparable 24-month clinical remission and safety to RTX + TAC in pMN, but with superior IR rates. These findings support B-cell depletion as a central therapeutic strategy, though long-term clinical benefits require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.